CR0300 Non-bisphosphonate-related osteonecrosis of the jaw

      Osteonecrosis of the jaw (ONJ) is a well-documented adverse effect associated with bisphosphonate therapy. Nonetheless, recently, other antiresorptive and antiangiogenic medications have also been implicated in ONJ. Previous case studies have reported ONJ in patients with exposure to denosumab (an inhibitor of receptor activator of nuclear factor κ B ligand), bevacizumab (a vascular endothelial growth factor inhibitor), and sunitinib (a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors among others). We report 5 patients with no known history of bisphosphonate administration who displayed clinical findings consistent with ONJ.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'